Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Maes et al
OMT-28, a selective PPAR- agonist, is currently being studied for its effects on atrial fibrillation and primary mitochondrial diseases (NCT05972954)
This review explores factors that may contribute to accelerated muscle loss among higher-risk patient populations and describes tailored interventions to reduce the risk of accelerated sarcopenia and frailty
These results suggest that acrolein resistance may be associated with higher glutathione production, though this relationship does not hold under all conditions
US$ 21.76
US$ 25.43
US$ 20.37
US$ 20.40
US$ 20.64
US$ 23.10
